William H Crown

List of Publications by Year
in descending order

59 papers	3,884 citations	201674 27 h-index	149698 56 g-index
61 all docs	61 docs citations	61 times ranked	4624 citing authors

#	Article	IF	Citations
1	How Can We Make More Rapid Progress in the Leveraging of Real-World Evidence by Regulatory Decision Makers?. Value in Health, 2022, 25, 167-170.	0.3	7
2	Machine Learning Methods in Health Economics and Outcomes Researchâ€"The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force. Value in Health, 2022, 25, 1063-1080.	0.3	24
3	Real-World Evidence: Understanding Sources of Variability Through Empirical Analysis. Value in Health, 2021, 24, 116-117.	0.3	6
4	Decomposition analysis as a framework for understanding heterogeneity of treatment effects in nonâ€randomized health care studies. Pharmaceutical Statistics, 2021, 20, 945-951.	1.3	0
5	Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment. JAMA Network Open, 2021, 4, e2130587.	5.9	28
6	Deep neural network models for identifying incident dementia using claims and EHR datasets. PLoS ONE, 2020, 15, e0236400.	2.5	20
7	Relative Cost Differences of Initial Treatment Strategies for Newly Diagnosed Opioid Use Disorder. Medical Care, 2020, 58, 919-926.	2.4	9
8	Assessing and communicating heterogeneity of treatment effects for patient subpopulations: Panel discussion on considerations in design and analysis. Pharmaceutical Statistics, 2020, 20, 952-964.	1.3	0
9	Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testingâ€"Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative. Value in Health, 2020, 23, 1128-1136.	0.3	68
10	The Potential Role of Constrained Optimization Methods in Healthcare Decision Making. Applied Health Economics and Health Policy, 2020, 18, 461-462.	2.1	2
11	Issues in the registration of database studies. Journal of Clinical Epidemiology, 2020, 121, 29-31.	5.0	7
12	Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Network Open, 2020, 3, e1920622.	5.9	505
13	Predicting Onset of Dementia Using Clinical Notes and Machine Learning: Case-Control Study. JMIR Medical Informatics, 2020, 8, e17819.	2.6	9
14	Real-World Evidence, Causal Inference, and Machine Learning. Value in Health, 2019, 22, 587-592.	0.3	38
15	Machine learning models to predict onset of dementia: A label learning approach. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 918-925.	3.7	41
16	Application of Constrained Optimization Methods in Health Services Research: Report 2 of the ISPOR Optimization Methods Emerging Good Practices Task Force. Value in Health, 2018, 21, 1019-1028.	0.3	36
17	Constrained Optimization Methods in Health Services Researchâ€"An Introduction: Report 1 of the ISPOR Optimization Methods Emerging Good Practices Task Force. Value in Health, 2017, 20, 310-319.	0.3	79
18	Working in the New Big Data World: Academic/Corporate Partnership Model. Computers in Health Care, 2017, , 157-180.	0.3	1

#	Article	IF	Citations
19	Specification Issues in a Big Data Context: Controlling for the Endogeneity of Consumer and Provider Behaviours in Healthcare Treatment Effects Models. Pharmacoeconomics, 2016, 34, 95-100.	3.3	5
20	Transforming Healthcare Delivery: Integrating Dynamic Simulation Modelling and Big Data in Health Economics and Outcomes Research. Pharmacoeconomics, 2016, 34, 115-126.	3.3	35
21	Can statistical linkage of missing variables reduce bias in treatment effect estimates in comparative effectiveness research studies?. Journal of Comparative Effectiveness Research, 2015, 4, 455-463.	1.4	1
22	Applying Dynamic Simulation Modeling Methods in Health Care Delivery Research—The SIMULATE Checklist: Report of the ISPOR Simulation Modeling Emerging Good Practices Task Force. Value in Health, 2015, 18, 5-16.	0.3	152
23	Potential Application of Machine Learning in Health Outcomes Research and Some Statistical Cautions. Value in Health, 2015, 18, 137-140.	0.3	80
24	Selecting a Dynamic Simulation Modeling Method for Health Care Delivery Research—Part 2: Report of the ISPOR Dynamic Simulation Modeling Emerging Good Practices Task Force. Value in Health, 2015, 18, 147-160.	0.3	109
25	Applications of propensity score methods in observational comparative effectiveness and safety research: where have we come and where should we go?. Journal of Comparative Effectiveness Research, 2014, 3, 63-78.	1.4	34
26	Optum Labs: Building A Novel Node In The Learning Health Care System. Health Affairs, 2014, 33, 1187-1194.	5.2	338
27	Propensity-Score Matching in Economic Analyses: Comparison with Regression Models, Instrumental Variables, Residual Inclusion, Differences-in-Differences, and Decomposition Methods. Applied Health Economics and Health Policy, 2014, 12, 7-18.	2.1	56
28	A Questionnaire to Assess the Relevance and Credibility of Observational Studies to Inform Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report. Value in Health, 2014, 17, 143-156.	0.3	96
29	Melding Regulatory, Pharmaceutical Industry, and U.S. Payer Perspectives on Improving Approaches to Heterogeneity of Treatment Effect in Research and Practice. Value in Health, 2013, 16, S10-S15.	0.3	8
30	The INITIATOR Study: Pilot Data on Real-World Clinical and Economic Outcomes in US Patients with Type 2 Diabetes Initiating Injectable Therapy. Advances in Therapy, 2013, 30, 1128-1140.	2.9	22
31	Looking to the Future: Incorporating Genomic Information into Disparities Research to Reduce Measurement Error and Selection Bias. Health Services Research, 2012, 47, 1387-1410.	2.0	10
32	Some Cautions on the Use of Instrumental Variables Estimators in Outcomes Research: How Bias in Instrumental Variables Estimators Is Affected by Instrument Strength, Instrument Contamination, and Sample Size. Value in Health, 2011, 14, 1078-1084.	0.3	46
33	Underutilization of BRCA1/2 testing to guide breast cancer treatment: Black and Hispanic women particularly at risk. Genetics in Medicine, 2011, 13, 349-355.	2.4	221
34	There¼s a Reason They Call Them Dummy Variables. Pharmacoeconomics, 2010, 28, 947-955.	3.3	11
35	Good Research Practices for Comparative Effectiveness Research: Analytic Methods to Improve Causal Inference from Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part III. Value in Health, 2009, 12, 1062-1073.	0.3	234
36	Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment. Leukemia and Lymphoma, 2006, 47, 1535-1544.	1.3	41

#	Article	IF	Citations
37	Utilization and Cost of Health Care Services Associated with Primary Malignant Brain Tumors in the United States. Journal of Neuro-Oncology, 2006, 81, 61-65.	2.9	27
38	Guidelines for selecting among different types of bootstraps. Current Medical Research and Opinion, 2006, 22, 799-808.	1.9	18
39	The Economic Burden of Anemia in Cancer Patients Receiving Chemotherapy. Value in Health, 2005, 8, 149-156.	0.3	61
40	Healthcare utilization among women who undergo surgery for stress urinary incontinence. International Urogynecology Journal, 2004, 15, 154-159.	1.4	13
41	Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast. Annals of Allergy, Asthma and Immunology, 2004, 92, 523-529.	1.0	22
42	The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Current Medical Research and Opinion, 2004, 20, 1929-1936.	1.9	53
43	The Cost Consequences of Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2004, 65, 341-347.	2.2	96
44	Clinical and economic effects of suboptimally controlled asthma. Managed Care Interface, 2004, 17, 31-6.	0.2	6
45	The family impact and costs of migraine. American Journal of Managed Care, 2004, 10, 313-20.	1.1	28
46	A retrospective claims analysis of the direct costs of stress urinary incontinence. International Urogynecology Journal, 2003, 14, 403-411.	1.4	18
47	A Checklist for Retrospective Database Studies—Report of the ISPOR Task Force on Retrospective Databases. Value in Health, 2003, 6, 90-97.	0.3	328
48	Seasonal versus Perennial Allergic Rhinitis: Drug and Medical Resource Use Patterns. Value in Health, 2003, 6, 448-456.	0.3	24
49	The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): An Instrument to Assess Outcomes of Schizophrenia Care. Schizophrenia Bulletin, 2003, 29, 247-256.	4.3	34
50	Measuring the costs and benefits of pharmaceutical expenditures. Expert Review of Pharmacoeconomics and Outcomes Research, 2002, 2, 467-475.	1.4	4
51	Treating allergic rhinitis in patients with comorbid asthma: The risk of asthma-related hospitalizations and emergency department visits. Journal of Allergy and Clinical Immunology, 2002, 109, 57-62.	2.9	316
52	The Impact of Treatment-Resistant Depression on Health Care Utilization and Costs. Journal of Clinical Psychiatry, 2002, 63, 963-971.	2.2	291
53	Treatment costs of venlafaxine and selective serotonin-reuptake inhibitors for depression and anxiety. Managed Care Interface, 2002, 15, 24-30.	0.2	4
54	Long-Term Costs of Treatment for Depression: Impact of Drug Selection and Guideline Adherence. Value in Health, 2001, 4, 295-307.	0.3	20

#	Article	IF	Citations
55	Panel 3: Methodological Issues in Conducting Pharmacoeconomic Evaluations—Retrospective and Claims Database Studies. Value in Health, 1999, 2, 82-87.	0.3	23
56	SSRI antidepressant use patterns and their relation to clinical global impression scores: a naturalistic study. Journal of Affective Disorders, 1999, 52, 111-119.	4.1	8
57	Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis. Journal of Affective Disorders, 1998, 47, 71-79.	4.1	56
58	The application of sample selection models to outcomes research: the case of evaluating the effects of antidepressant therapy on resource utilization. , 1998, 17, 1943-1958.		46
59	Economic consequences of selective serotonin reuptake inhibitor use with drugs also metabolized by the cytochrome P-450 system. Clinical Therapeutics, 1998, 20, 780-796.	2.5	9